BioPharma Dive October 1, 2024
Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex’s dominant cystic fibrosis business.
It’s not a well-known disease. But transthyretin amyloidosis cardiomyopathy, a rare condition affecting the heart, has become the target of a major drug development effort.
One medicine, from Pfizer, is approved and two others, from BridgeBio Pharma and Alnylam Pharmaceuticals, have succeeded in late-stage testing. Deciding which offers the greatest benefit has consumed analysts on Wall Street and top experts in the field. At stake is a market worth billions of dollars.
By Thanksgiving, the Food and Drug Administration is expected to decide on approval of BridgeBio’s acoramidis, likely...
Today's Sponsors
Today's Sponsor